News | December 09, 2022
Emmes launches Cell and Gene Therapy Center
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
There is also a growing interest in whole generation sequencing (WGS)
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Subscribe To Our Newsletter & Stay Updated
